What Is Charles River and Why Do Biotechs Need It?
Charles River is the company biotechs and drug makers hire to test a new drug before it is given to people. It breeds the research animals (mostly purpose-bred rats and mice), runs the safety studies regulators require, and tests the quality of biologic drugs.
- Revenue was about $4.0 billion in 2025, and in the second quarter of 2026 organic growth turned positive at 0.1%, the first increase since the third quarter of 2023, as biotech funding recovered to nearly $100 billion over twelve months.
- The risk is structural: regulators are encouraging alternatives to animal testing.
- Management says the change will be gradual and is building alternatives itself.
- The shares closed at $345.37, at their 52-week high.
This is analysis, not a recommendation.
What does Charles River do?
| Segment | What it does | Share of 2025 revenue | Q2 2026 revenue |
|---|---|---|---|
| Discovery and Safety Assessment (DSA) | Outsourced drug discovery and the regulated safety testing needed before human trials | 59.8% | $606.5 million |
| Research Models and Services (RMS) | Breeds and sells purpose-bred rodents (over 140 stocks and strains) and other models to academic and drug labs | 21.1% | $209.5 million |
| Manufacturing Solutions | Tests and makes products for biologics, such as microbial and endotoxin quality tests | 19.1% | $188.1 million |
Charles River's Q2 2026 revenue by segment, from its call. Total revenue was about $1.0 billion.
The 10-K says the FDA and foreign regulators require that most new drug candidates be tested on research models before human trials, which is why biotechs pay for this work. No single client was more than 4% of 2025 revenue, and the company operates over 120 sites in more than 20 countries.
How is the business doing?
| Measure | Q2 2026 | Note |
|---|---|---|
| Revenue | About $1.00 billion | Down 2.7% reported after divestitures, up 0.1% organic, the first organic rise since Q3 2023 |
| Non-GAAP EPS | $3.02 | Down 3.2% on the year, up 47% on the quarter |
| DSA net book-to-bill | 1.19 | The highest in nearly four years, with backlog of $1.97 billion |
| Non-GAAP operating margin | 20.5% | Up 4.2 points on the quarter |
| 2026 non-GAAP EPS guide | $11.15 to $11.45 | Raised by $0.25 at the midpoint, 8% to 11% growth |
| 2026 organic revenue guide | Flat to up 1% | Raised by 1.5 points |
| 2026 free cash flow guide | $400 to $420 million | Raised from $375 to $400 million |
A book-to-bill above 1 means customers are placing more orders than the company completes, which points to future revenue. Management said trailing twelve-month biotech funding was nearly $100 billion, just shy of the pandemic peak, and that global biopharma customers are booking more work, though pricing has not materially improved. Small and mid-size biotech revenue was essentially flat, and flat NIH budgets continue to hold back the models business.
Will less animal testing hurt Charles River?
This is the main long-term question. The FDA announced in April 2025 that it would reduce animal testing in preclinical safety studies, and the scientific community is developing new approach methodologies (NAMs), such as computer models and lab-grown tissues. Charles River's filings say NAMs may supplement and in some cases replace current methods, that eliminating animals will be gradual and may take many years, and that complete elimination could have a material adverse effect on the business.
| How Charles River is responding | Detail |
|---|---|
| Leadership | A Scientific Advisory Board on NAMs (October 2025) and a Chief Scientific and Innovation Officer (January 2026) |
| Strategy | NAMs built into its safety workflows, not a separate business, with partnering and licensing; the company also uses virtual control groups to reduce animal numbers |
| Acquisitions | PathoQuest (in vitro sequencing for biologics quality control) in April 2026 |
| Investor Day | Held on September 24, 2026; its content was not read for this post |
What other risks and levers are there?
- Monkey supply: most non-human primates are used in its safety studies, and it now owns farms in Mauritius and Cambodia (acquired January 2026), which management says gives control of quality and timing and lower costs from the fourth quarter.
- Margin repair: about half of the second-half improvement comes from completed divestitures and lower primate costs, and about 1.5 points from lower corporate costs.
- Tax and budgets: a proposed foreign tax change is a $0.20 EPS headwind, and NIH funding is flat.
- Capital returns: $300 million of buybacks so far in 2026, with net leverage at 2.5 times.
How does CRL look on this site's checks?
From the weekly data of October 23, 2026, on the Charles River stock page:
| Measure | CRL | What it tells you |
|---|---|---|
| Price | $345.37 | At its 52-week high of $351.21 |
| Market value | $16.5 billion | Total value of all shares |
| Trailing / forward P/E | n/a / 30.4 | No trailing P/E because of a trailing loss, forward is on 2026 estimates |
| Price to sales / price to book | 4.1 / 5.8 | This site's limits are 7 and 8 |
| Revenue growth / net margin | -0.7% / -6.0% | Trailing twelve months, with divestitures and a loss in the net margin |
| Debt to equity | 0.93 | Total debt against shareholders' equity |
| 1-year change / RSI | +84.7% / 73.2 | A year of strong gains, and above 70 is overbought |
| Value filters passed | 3 of 8 | This site's eight mechanical value filters |
| Margin of safety (DCF) | -150.1% | A neutral model that fades growth from 8% to 2.5% |
After an 85% rise the stock already prices the recovery: this site's reverse DCF needs free cash flow per share to grow about 32% a year. What growth does a share price imply explains how to read that.
What should you read next?
Two more explainers on companies in the same screen: how does Schwab earn money from your cash, and how does Carvana make money selling used cars.
Sources
- Charles River Q2 2026 earnings call transcript (Motley Fool, August 2026): results, guidance, supply, NAMs commentary
- Charles River fiscal 2025 annual report on Form 10-K (SEC): business, segments and risks
- Charles River on this site: price and ratios, October 23, 2026
The company's release could not be read and part of the 10-K risk section was read only as a summary. The FDA's April 2025 plan is described from the company's filings as reported, and Investor Day content and any activist involvement were not found. This is educational content, not investment advice.
Charles River FAQ
What does Charles River do?
It supplies research animals, runs safety and discovery studies for drug makers, and tests biologic drugs, with most revenue from safety assessment.
Why do biotechs need Charles River?
Regulators require most new drug candidates to be tested on research models before human trials, and biotechs outsource that work.
Is Charles River growing?
Organic revenue turned positive at 0.1% in Q2 2026, the first rise since 2023, and 2026 guidance was raised to flat to up 1% organic.
Will alternatives to animal testing hurt it?
They could over time, and the company says elimination will be gradual. It is building alternatives into its workflows, but the risk is real.
How is Charles River's stock doing?
It is at its 52-week high of about $351, up about 85% in a year, with a forward P/E near 30.